ACA
RPRX icon

Atlas Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Atlas Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Hold
5,727
– – 0.03% 364
2025
Q4 		$221K Buy
+5,727
New +$218K 0.02% 396
2025
Q2 		$167K Hold
4,639
– – 0.02% 440
2025
Q1 		$144K Buy
+4,639
New +$147K 0.02% 462

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Atlas Capital Advisors's RPRX Position: Q1 2026 in Review

Atlas Capital Advisors held its Royalty Pharma (RPRX) position steady in Q1 2026 at 5,727 shares worth $275K. The position accounts for 0.03% of the portfolio, ranked #364.

Atlas Capital Advisors first reported a position in RPRX in Q1 2025 and has held it in 4 quarters since. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Atlas Capital Advisors held 5,727 shares of Royalty Pharma worth $275K as of Q1 2026.
  • Atlas Capital Advisors left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up 0.03% of Atlas Capital Advisors's portfolio in Q1 2026, its #364 holding.
  • Atlas Capital Advisors first reported a position in Royalty Pharma in Q1 2025 and has held it in 4 quarters since.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.